Vanguard Group Inc Clovis Oncology, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.85 $1.07 Million - $2.9 Million	-1,016,728 Reduced 9.06%	10,206,509 $12.1 Million
Q2 2022 Aug 12, 2022	SELL	$0.63 - $2.96 $709,166 - $3.33 Million	-1,125,661 Reduced 9.12%	11,223,237 $20.2 Million
Q1 2022 May 13, 2022	BUY	$1.43 - $3.14 $3.19 Million - $7.01 Million	2,233,797 Added 22.08%	12,348,898 $24.9 Million
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $5.89 Million - $10.4 Million	-2,179,790 Reduced 17.73%	10,115,101 $27.4 Million
Q3 2021 Nov 12, 2021	BUY	$4.06 - $5.8 $9.67 Million - $13.8 Million	2,380,823 Added 24.01%	12,294,891 $54.8 Million
Q2 2021 Aug 13, 2021	BUY	$5.02 - $7.05 $49.8 Million - $69.9 Million	9,914,068 New	9,914,068 $57.5 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.